Menu
Recruiting NCT05022264

Remote Investigation and Assessment of Vital Signs

— Observational Blood Pressure Pulse Rate Respiratory Rate Oxygen Saturation

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: RIA-VS.
Who it may be relevant to
Registry conditions: Blood Pressure, Pulse Rate, Respiratory Rate, Oxygen Saturation. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Sweden
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The vital signs (pulse, systolic and diastolic blood pressure, respiratory rate, oxygen saturation and body temperature) are critical in assessing the severity and prognosis of infections. The devices used today for measuring the vital signs have to be in physical contact with the patients. There is an apparent risk of transferring infections from one patient to the next (or to healthcare professionals). Accurately obtaining vital signs is also important when managing other categories of patients where it may be relevant to obtain some of the vital signs such as pulse and blood pressure. This project aims to evaluate a new camera-based system for contactless measurement of vital signs.

Detailed description

STUDY DESIGN:

A method comparison design with three work packages (WP):

WP1: Focus on estimating validity and reliability of the new study device to measure body temperature.

WP2: Focus on estimating validity and reliability of the new study device to measure all vital signs except body temperature (pulse, systolic and diastolic blood pressure, respiratory rate and oxygen saturation).

WP3: Focus on estimating if there is any difference in the validity and reliability of the new study device to measure all vital signs (except body temperature) in subjects with Fitzpatrick skin type 5-6 as compared with those of skin type 1-4.

STUDY POPULATION:

WP1: Patients aged ≥18 years admitted to or attending a hospital clinic. WP2: Patients aged ≥18 year attending primary health care or patients being admitted to a hospital clinic.

WP3: Individuals aged ≥18 years attending primary health care.

Interventions

  • Diagnostic test RIA-VS
    Measuring vital signs with a new contactless camera technique

Primary outcome measures

  • Agreement between conventional techniques and the new RIA-VS device [Time frame: The time delay between the measurements using conventional techniques and the new RIA-VS device will be approximately 5 minutes]
Secondary outcome measures (2)
  • Estimate test-retest reliability of the new RIA-VS device [Time frame: The time delay between the measurements using conventional techniques and the new RIA-VS device will be approximately 5 minutes]
  • Evaluate the influence of different skin types on the validity of the new RIA-VS study device [Time frame: The time delay between the measurements using conventional techniques and the new RIA-VS device will be approximately 5 minutes]

Eligibility criteria

Inclusion criteria

The same subject can't be enrolled more than once with the exception that subjects in WP1 may also be recruited to WP2.

WP1+WP2:

  • The patient is attending primary or secondary health care.
  • The subject has provided informed consent.
  • Age ≥18 years.
  • Fluent in Swedish, English, Somali or Arabic (we will translate the patient information and ensure an interpreter can be present for translating questions).
  • The patient is willing and able to give informed consent ".
  • The investigator determines that the new study device, and the reference methods, can be used as intended with adequate safety.
  • The delay in the management of each patient introduced by this study is approximately 15-20 minutes. Patients deemed being in such a severe medical condition that 15-20 minutes of delay is deemed detrimental will not be included.

WP3:

  • Patients attending primary health care.
  • The subject has provided informed consent.
  • Age ≥18 years.
  • Fluent in Swedish, English, Somali or Arabic (we will translate the patient information and ensure an interpreter can be present for translating questions).
  • The patient is willing and able to give informed consent .
  • The investigator determines that the new study device, and the reference methods, can be used as intended with adequate safety.
  • The delay in the management of each patient introduced by this study is approximately 15-20 minutes. Patients deemed being in such a severe medical condition that 15-20 minutes of delay is deemed detrimental will not be included.

Exclusion criteria

Subjects are free to withdraw from the study at any point. Subjects will also be withdrawn from the study in case of unexpected depressed level of consciousness from inclusion up until all investigations are completed (during approximately 15-20 minutes). Any reduction in consciousness will incur that the subject is withdrawn.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Other

Study locations

Sweden · 1 center
  • Hälsobrunnen Vårdcentral — Ulricehamn

Identifiers

NCT: NCT05022264 · U1111-1261-8273

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗